(Q46689239)

24 December 2017

title

Long-acting risperidone in stable patients with schizoaffective disorder (English)

1 reference

24 December 2017

1 reference

6

1 reference

24 December 2017

Stein Opjordsmoen Ilner

3

object named as

Opjordsmoen S

1 reference

24 December 2017

Mohl A

1

1 reference

24 December 2017

Westlye K

2

1 reference

24 December 2017

Lex A

4

1 reference

24 December 2017

Schreiner A

5

1 reference

24 December 2017

Bräunig P

7

1 reference

24 December 2017

Medori R

8

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

24 December 2017

Journal of Psychopharmacology

published in

1 reference

24 December 2017

volume

19

1 reference

24 December 2017

issue

5 Suppl

1 reference

24 December 2017

page(s)

22-31

1 reference

24 December 2017

Consensus development conference on antipsychotic drugs and obesity and diabetes

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Clinical profile of an atypical antipsychotic: risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Determinants of medication compliance in schizophrenia: empirical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Complications at site of injection of depot neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Does risperidone have a place in the treatment of nonschizophrenic patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Psychosocial correlates of prepartum and postpartum depressed mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Factors influencing the long-term outcome of schizoaffective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056515

21 January 2018

Identifiers

DOI

10.1177/0269881105056515

1 reference

24 December 2017

1 reference

24 December 2017